FMP
Enanta Pharmaceuticals, Inc.
ENTA
NASDAQ
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
6 USD
-0.105 (-1.75%)
Earnings
We are unable to load the chart at this time.
Dividends
We are unable to load the chart at this time.
Splits
We are unable to load the chart at this time.
From:
To:
Date
Revenue
Earnings
Estimated Earnings
Surprise
No data found!
